Shares of Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) have been given an average rating of “Moderate Buy” by the thirteen ratings firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $44.60.
Several analysts have recently issued reports on IMVT shares. UBS Group reiterated a “buy” rating on shares of Immunovant in a research note on Wednesday, September 23rd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Immunovant in a research report on Tuesday, August 25th. HC Wainwright restated a “buy” rating on shares of Immunovant in a report on Thursday, September 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunovant in a report on Friday, October 2nd. Finally, Citigroup reissued a “positive” rating on shares of Immunovant in a report on Thursday, September 24th.
View Our Latest Research Report on IMVT
Immunovant Price Performance
IMVT stock opened at $33.17 on Thursday. The stock has a market capitalization of $6.86 billion, a PE ratio of -12.96 and a beta of 0.95. Immunovant has a fifty-two week low of $21.86 and a fifty-two week high of $45.42. The company has a 50 day moving average price of $32.28 and a 200 day moving average price of $32.44.
Immunovant (NASDAQ:IMVT – Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.27. During the same quarter last year, the firm posted ($0.73) earnings per share. As a group, equities analysts expect that Immunovant will post -2.49 earnings per share for the current fiscal year.
Insider Buying and Selling at Immunovant
In related news, CTO Jay S. Stout sold 3,809 shares of the company’s stock in a transaction on Wednesday, October 7th. The shares were sold at an average price of $32.06, for a total value of $122,116.54. Following the sale, the chief technology officer directly owned 201,532 shares of the company’s stock, valued at $6,461,115.92. This represents a 1.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Tiago Girão sold 6,606 shares of the business’s stock in a transaction dated Wednesday, October 28th. The stock was sold at an average price of $28.50, for a total transaction of $188,271.00. Following the completion of the sale, the chief financial officer owned 234,192 shares in the company, valued at approximately $6,674,472. This trade represents a 2.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 27,430 shares of company stock valued at $895,852. Insiders own 1.90% of the company’s stock.
Institutional Investors Weigh In On Immunovant
Several hedge funds have recently made changes to their positions in IMVT. GAMMA Investing LLC boosted its holdings in shares of Immunovant by 63.6% in the 3rd quarter. GAMMA Investing LLC now owns 1,224 shares of the company’s stock worth $41,000 after acquiring an additional 476 shares in the last quarter. Quantbot Technologies LP bought a new position in Immunovant during the 2nd quarter worth $87,000. Sterling Capital Management LLC grew its position in Immunovant by 856.0% during the third quarter. Sterling Capital Management LLC now owns 2,868 shares of the company’s stock worth $97,000 after buying an additional 2,568 shares in the last quarter. Nykredit A S bought a new stake in Immunovant during the second quarter worth about $174,000. Finally, State of Wyoming bought a new stake in Immunovant during the second quarter worth $208,000. Institutional investors own 47.08% of the company’s stock.
Immunovant Company Profile
Immunovant, Inc. is a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases. Its research focuses on inhibiting the neonatal Fc receptor (FcRn), a pathway involved in maintaining levels of disease-causing antibodies. The company’s investigational medicines include batoclimab and IMVT-1402, both designed to reduce circulating antibodies. Immunovant has studied or evaluated these candidates for conditions including myasthenia gravis, Graves’ disease and other autoimmune disorders.
Further Reading
- Five stocks we like better than Immunovant
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Immunovant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunovant and related companies with MarketBeat.com's FREE daily email newsletter.
